-
公开(公告)号：KR1019920006911B1
公开(公告)日：1992-08-22
申请号：KR1019890008200
申请日：1989-06-14
Applicant: 신풍제약주식회사
IPC: A61K31/54
Abstract: A stable piroxicam injection compsn.contains piroxicam as an effective ingredient, 1.1 - 1.2 mole of L-arginine or L-lysine (relative to 1 mole piroxicam) as a solubilizing agent, 15-25 W/V % of propylene glycol mixture and 1-2 W/V % of polyvinyl pyrrolidone. Also claimed is the prepn. of the compsn. which comprises dissolving piroxicam with L-arginine, L-lysine and propylene glycol in distilled water for injection, and adding polyvinyl pyrrolidone into the obtd. soln as a stabilizer. Piroxicam is useful as a nonsteroidal antiphlogistic analgesic.
Abstract translation: 稳定的吡罗昔康注射剂含有炎痛喜糖作为有效成分，1.1-1.2摩尔L-精氨酸或L-赖氨酸（相对于1摩尔吡罗昔康）作为增溶剂，15-25W / V％的丙二醇混合物和1 -2W / V％的聚乙烯吡咯烷酮。 还声称是prepn。 的compsn。 其中包括将吡罗昔康与L-精氨酸，L-赖氨酸和丙二醇溶解在用于注射的蒸馏水中，并将聚乙烯吡咯烷酮加入到该溶液中。 soln作为稳定剂。 吡罗昔康作为非甾体类消炎止痛药有用。
-
公开(公告)号：KR102209441B1
公开(公告)日：2021-01-29
申请号：KR1020160113284
申请日：2016-09-02
Applicant: 신풍제약주식회사
IPC: C07D495/04 , C07D261/20 , C07D413/04 , A61K31/4365 , A61K31/423 , A61K31/5375
Abstract: 본발명은혈소판응집저해효과를갖는신규한화합물및 그염류에관한것으로서, 더욱상세하게는전단응력에의한혈소판응집(shear stress-induced platelet aggregation)을선택적으로저해하는새로운혈소판응집저해제및 이를유효성분으로하는약학적조성물및 그제조방법에관한것이다.
-
公开(公告)号：KR1020120006451A
公开(公告)日：2012-01-18
申请号：KR1020110068627
申请日：2011-07-11
Applicant: 신풍제약주식회사 , 포항공과대학교 산학협력단
CPC classification number: A61K8/735 , A61K31/167 , A61L27/20 , A61L27/52 , A61L27/54 , A61L2300/402 , A61L2400/06 , A61Q19/08 , C08B37/0072 , C08J3/075 , C08J2305/08 , C08L5/08
Abstract: PURPOSE: A filler composition for reinforcing tissue and a manufacturing method thereof are provided to be injected into biological tissue by being charged with injections easily to maintain the characteristic including viscoelasticity, and the like steadily after sterilization, and to enhance biocompatibility. CONSTITUTION: A filler composition for reinforcing tissue includes a hyaluronic acid of the following equation and a hydro gel of alkylendiamine crosslinking materials The equation is expressed as [HA]m-C(O)-NH-R1-NH-C(O)-[HA]n, wherein HA indicates the hyaluronic acid except a carboxyl group or its salt, R1 shows hydroxyl group, and C1-C6 indicate alkyl group, C3-C10 alkylene functional group which is substituted as C1-C6 alkoxy, or which is non-subjstituted, and m and n indicate integer ranged 10,000-4,000,000. The molecular weight of the hyaluronic acid is from 20,000 to 40,000 dalton.
Abstract translation: 目的：提供一种用于增强组织的填充剂组合物及其制造方法，其通过在灭菌后容易地维持包括粘弹性等特性等特性的注射剂注入生物体组织，并提高生物相容性。 构成：用于增强组织的填充剂组合物包括以下等式的透明质酸和烷基二胺交联材料的水凝胶。该方程式表示为[HA] mC（O）-NH-R 1 -NH-C（O） - [HA ] n，其中HA表示除了羧基或其盐以外的透明质酸，R1表示羟基，C1-C6表示烷基，作为C1-C6烷氧基取代的C3-C10亚烷基官能团， 取代，m和n表示整数范围为10,000-4,000,000。 透明质酸的分子量为20,000至40,000道尔顿。
-
公开(公告)号：KR101075435B1
公开(公告)日：2011-10-24
申请号：KR1020090001655
申请日：2009-01-08
Applicant: 신풍제약주식회사
IPC: C07D239/96 , A61K31/517 , A61P25/28 , A61P25/08
CPC classification number: C07D403/12 , C07D239/96
Abstract: p는 0 또는 1의정수이다.
-
公开(公告)号：KR101062320B1
公开(公告)日：2011-09-05
申请号：KR1020080074260
申请日：2008-07-29
Applicant: 신풍제약주식회사 , 포항공과대학교 산학협력단
IPC: C08B37/08
Abstract: 본 발명은 가교결합성 히알루론산(hyaluronic acid, HA) 유도체 제조방법 및그 히알루론산 유도체의 가교결합물에 관한 것으로서, 더욱 상세하게는, 물-알코올 혼합용매 중에서 히알루론산 또는 그의 염 또는 유도체를 카르복실기 활성화제의 존재하에 지방족 디카르복실산의 디하이드라자이드 화합물과 반응시키는 단계를 포함하는 히알루론산 유도체 제조방법 및 이에 따라 제조된 히알루론산 유도체의 가교결합물에 관한 것이다. 본 발명에 따른 히알루론산 유도체의 가교결합물은 겔, 주름살 치료용 삽입물, 성형보조물, 관절염 치료용 삽입물, 약물 전달체 등의 다양한 생체적합성(biocompatibility) 소재로 사용될 수 있다.
가교결합성, 히알루론산, 유도체, 가교결합물, 제조방법-
Patent Agency Ranking
公开(公告)号：KR1020100057423A
公开(公告)日：2010-05-31
申请号：KR1020080116461
申请日：2008-11-21
Applicant: 신풍제약주식회사
IPC: A61K47/48 , A61K31/192 , A61K47/06
CPC classification number: A61K31/192 , A61K9/0053 , A61K47/02 , A61K47/183
Abstract: PURPOSE: A method for preparing dexibuprofen salt and a pharmaceutical composition for oral administration containing the same are provided to enhance release rate and to reduce side effect. CONSTITUTION: A method for preparing a dexibuprofen salt comprises: a step of dissolving dexibuprofen and inorganic base or organic base in two kinds of more polar solvent; a step of adding acetone to crystallize; and a step of drying crystal. The inorganic base or organic base is arginine, lysine, histidine, ornithine, NH4OH, NaOH, or KOH. A pharmaceutical composition contains the dexibuprofen salt and pharmaceutically acceptable carrier. A pharmaceutical composition for oral administration is used in the form of tablet, capsule, granule, pill, or liquid.
Abstract translation: 目的：提供一种制备右旋布洛芬盐的方法和含有这些组合物的用于口服给药的药物组合物以提高释放速率并降低副作用。 构成：一种制备右布洛芬盐的方法，其特征在于，将二苯丙酮酸和无机碱或有机碱溶解在两种极性较大的溶剂中的步骤; 加入丙酮结晶的步骤; 以及干燥晶体的步骤。 无机碱或有机碱是精氨酸，赖氨酸，组氨酸，鸟氨酸，NH 4 OH，NaOH或KOH。 药物组合物含有对映布洛芬盐和药学上可接受的载体。 用于口服给药的药物组合物以片剂，胶囊剂，颗粒剂，丸剂或液体的形式使用。
-
公开(公告)号：KR1020090013696A
公开(公告)日：2009-02-05
申请号：KR1020080074260
申请日：2008-07-29
Applicant: 신풍제약주식회사 , 포항공과대학교 산학협력단
IPC: C08B37/08
CPC classification number: C08B37/0072 , A61K47/36 , A61L27/20 , A61L27/54 , C08J3/24
Abstract: A method for preparing a crosslinkable hyaluronic acid derivative is provided to ensure excellent bio compatibility, high viscoelasticity and superior stability to a hyaluronidase, and to be used as various bio compatibility materials of gel, insert for treating wrinkle, molding subsidiary material, insert for treating arthritis and drug carrier. A crosslinkable hyaluronic acid derivative of the chemical formula 1: [HA]-C(O)-NHNH-C(O)-R^1-C(O)-NHNH2 is prepared by reacting a hyaluronic acid or their salt or derivative, with a dihydrazide compound of an aliphatic dicarboxylic acid represented by the following chemical formula 2: H2N-NH-C(O)-R^1-C(O)-NHNH2, in the water-alcohol mixed solvent, in the presence of a carboxyl group activating agent. In the formulae, [HA] shows a hyaluronic acid except for a carboxyl group or their salt or derivative, and R^1 shows substituted or unsubstituted C3-C10 alkylene radical.
Abstract translation: 提供制备交联性透明质酸衍生物的方法，以确保优异的生物相容性，高粘弹性和对透明质酸酶的优异稳定性，并且用作凝胶的各种生物相容性材料，用于治疗皱纹的插入物，模制辅助材料，用于治疗的插入物 关节炎和药物载体。 化学式1：[HA] -C（O）-NHNH-C（O）-R 1 C（O）-NHNH 2的交联性透明质酸衍生物是通过使透明质酸或其盐或衍生物， 与由以下化学式2表示的脂族二羧酸的二酰肼化合物：在水 - 醇混合溶剂中，在水 - 醇混合溶剂中，在存在下列化学式2的情况下，将H 2 N-NH-C（O）-R 1 羧基活化剂。 在该式中，[HA]表示除羧基以外的透明质酸或其盐或衍生物，R 1表示取代或未取代的C 3 -C 10亚烷基。
-
38.发明授权(±)-2-(4-클로로벤조일아미노)-3-[2(1Ｈ)-퀴놀리논-4-일]프로피오닉산의 제조 방법 失效（±）-2-（4-클로로벤조일아미노）-3- [2（1H） - 퀴놀리논-4-일]프로피오닉산의제조방（
公开(公告)号：KR100439733B1
公开(公告)日：2004-07-12
申请号：KR1020020000516
申请日：2002-01-04
Applicant: 신풍제약주식회사
IPC: C07D215/14
Abstract: PURPOSE: Provided is (±)-2-(4-chlorobenzoylamino)-3-(2(1H)-quinolinone-4-mono)propionic acid which is prepared through simplified processing steps at high yield and high purity. CONSTITUTION: 4-halomethyl-2(1H)-quinolinone(formula III) reacts with dialkyl 4-chlorobenzoylamino malonate(formula IV) in the presence of an inorganic base in an alcoholic solvent to prepare alkyl 2-(4-chlorobenzoylamino)-2-(alkoxycarbonyl)-3-(2(1H)-quinolinone-4-mono)propionate(formula II) as an intermediate. It selectively suffers decarboxylation and hydrolysis using an acids mixture wherein acetic acid is mixed with other acids in a volume ratio of 1:0.3-10.2, thereby preparing the (±)-2-(4-chlorobenzoylamino)-3-(2(1H)-quinolinone-4-mono)propionic acid(formula I). In the formulas, R is C1-6 alkyl group, and X1 is halogen.
Abstract translation: 目的：提供通过简单的加工步骤以高收率和高纯度制备的（（±）） - 2-（4-氯苯甲酰氨基）-3-（2（1H） - 喹啉酮-4-单）丙酸。 结构式：4-卤代甲基-2（1H） - 喹啉酮（式III）与无水碱存在下在醇溶剂中与4-氯苯甲酰氨基丙二酸二烷基酯（式IV）反应，制得2-（4-氯苯甲酰氨基）-2 - （烷氧基羰基）-3-（2（1H） - 喹啉酮-4-酮）丙酸酯（式II）。 由此制备（±）-2-（4-氯苯甲酰基氨基）-3-（ 2（1H） - 喹啉酮-4-单）丙酸（式I）。 在通式中，R是C 1-6烷基，并且X 1是卤素。
-
公开(公告)号：KR100360828B1
公开(公告)日：2002-11-13
申请号：KR1019990065917
申请日：1999-12-30
Applicant: 신풍제약주식회사
IPC: A61K31/495
CPC classification number: A61K9/1652 , A61K9/2013 , A61K9/2054 , A61K31/4985
Abstract: 본발명은프라지콴텔을유효성분으로포함하고, 고분자물질및 결합제를적절히선택하여배합함으로써프라지콴텔의방출속도를조절한서방성구충제조성물에관한것이다.
-
公开(公告)号：KR100294149B1
公开(公告)日：2001-09-17
申请号：KR1019950067279
申请日：1995-12-29
Abstract: PURPOSE: Provided are a method for separation and purification of fibrinolytic enzyme from the extract of Earthworm, and cDNA gene coding the fibrinolytic enzyme. CONSTITUTION: The fibrinolytic enzyme is prepared from the extract of Earthworm by cation-exchange column chromatography; hydrophobic binding chromatography; affinity chromatography using benzamide as a ligand; and affinity chromatography using Lima Bean Trypsin inhibitor as a ligand.
-
-
-
-
-
-
-
-
-
Search Results
84
records
(took 0.022 seconds)
